The MRC Clinical Trials Unit (CTU) is a centre of excellence for clinical trials, meta-analyses and epidemiological studies.
We are committed to strengthening and expanding the evidence-base for healthcare nationally and internationally.
The MRC CTU is a UKCRC registered trials unit.
Read more about the Unit
Adding the drug bevacizumab to chemotherapy for ovarian cancer can slow down the disease and may improve overall survival in women at high risk of recurrence, according to new research from an international research team led by the Medical Research Council, St James’s Institute of Oncology in Leeds, and the Princess Margaret Hospital, Toronto.
Read full report
More news and press releases
Our Research Areas
